ERBB2 and breast carcinoma: A study by Singer and colleagues showed that early breast cancer patients with a HER2/CEP17 ratio of >6 had significantly higher rates of pCR to neoadjuvant trastuzumab treatment than those with low HER2 amplification levels [20].